Enveric Biosciences Canada Inc.

Enveric Biosciences Canada Inc. is a Canadian subsidiary of Enveric Biosciences, Inc., a publicly traded biotechnology company headquartered in Cambridge, Massachusetts, USA. Enveric Biosciences, Inc. (NASDAQ: ENVB) was founded in 1994 and maintains an office in Calgary, Alberta, Canada, along with other locations. As of December 31, 2025, the parent company reported 6 employees and had a market capitalization of approximately $7.92 million as of May 1, 2026. Enveric Biosciences, Inc. is currently a pre-revenue company, focusing its resources on research and development.

Enveric Biosciences, Inc. is dedicated to the discovery and development of novel neuroplastogenic small-molecule therapeutics to address unmet needs in psychiatric and neurological disorders such as depression, anxiety, addiction, and post-traumatic stress disorder. The company leverages its proprietary discovery platform, "The Psybrary™," to create a robust intellectual property portfolio of new chemical entities. Its lead candidate, EB-003 (part of the EVM301 series), is in preclinical development and is designed to promote neuroplasticity without inducing hallucinations. Enveric also develops the EVM401 series for addiction and neuropsychiatric conditions and has out-licensed other patented drug candidates, including a cannabinoid crème technology for radiation dermatitis.

Enveric Biosciences Canada Inc. appears in the patent litigation database as a defendant in one case. This case, "Unknown Petitioner v. Enveric Biosciences Canada Inc.," was a Post-Grant Review (PGR) petition filed at the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO). The litigation posture indicates Enveric Biosciences is an operating company actively defending its intellectual property, rather than asserting patents as a non-practicing entity.

The notable PTAB case involved a challenge by Gilgamesh Pharmaceuticals against Enveric's U.S. Patent No. 12,138,276, which pertains to halogenated psilocybin derivatives. Gilgamesh Pharmaceuticals was subsequently acquired by AbbVie Inc., which also acquired the bretisilocin (GM-2505) molecule relevant to the patent. The PGR petition against Enveric's patent was ultimately withdrawn in February 2026, resulting in no remaining challenges to that specific patent. The parent company, Enveric Biosciences, Inc., has continued to expand its intellectual property portfolio with new U.S. patents issued in 2026 for its EVM301 and EVM401 series of molecules.